Comment on

• Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

  Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Catalona WJ, et al. JAMA. 1998 May 20;279(19):1542-7. doi: 10.1001/jama.279.19.1542. JAMA. 1998. PMID: 9605898 Clinical Trial.